1. Introduction {#s0005}
===============

There is a growing interest in the development of new antibacterial agents as a consequence to the gradual growth of bacterial resistance toward a variety of agents; besides, with the alarming rise of multi-drug resistance bacterial species ([@b0185]); nowadays, physicians are forced to prescribe the second or even third option of antibiotic to fight these resistant bacteria ([@b0135]).

With their origin firmly established in organic and medicinal chemistry, heterocyclic compounds introduce themselves as an essential sort of organic chemicals; they are defined by IUPAC as "cyclic compounds having, as ring members, atoms of at least two different elements" ([@b0085]). In accordance with heteroatom(s) present in the ring system, heterocycles can be grouped as oxygen, nitrogen or sulfur-based orderliness; within each group, they are also organized according to the size of ring structure that is determined by the total number of atoms ([@b0170]). The type of heteroatom and the ring size along with the substituent groups on the lead structure are the principal determinants of heterocycle's physicochemical properties ([@b0130]). Although there is a massive number of pharmacologically active heterocyclic compounds acting as antitumor ([@b0045], [@b0145], [@b0005]), anti-fungal ([@b0035], [@b0050], [@b0200]), anti-viral ([@b0195], [@b0065], [@b0025]), anti-inflammatory ([@b0110], [@b0120], [@b0090]) and anticonvulsant ([@b0190], [@b0165], [@b0155]), an increasing number of heterocycles have shown a potent antibacterial effect ([@b0030], [@b0095], [@b0040]).

Among the different biologically active oxygenated heterocyclic compounds, coumarin ([Fig. 1](#f0005){ref-type="fig"}) and its derivatives have become a fascinating subject of research due to their broad distribution in nature and their well-defined synthetic reactions ([@b0020], [@b0075], [@b0080]). Also, they serve as important precursors for advanced design and synthesis of more pharmacologically active compounds ([@b0175], [@b0100], [@b0180]).Fig. 1Chemical structure of coumarin.

The aim of this work is the synthesis of heterocyclic compounds containing a novel chemical nucleus herein called coumacine that has not been synthesized before with the testing of their spectrum of antibacterial activity through achieving the following objectives: synthesis of these compounds from coumarins, detecting the kinetics of their ring closure, and testing there *in vitro* antibacterial activity against different standard aerobic and anaerobic bacterial strains using ciprofloxacin and metronidazole as positive controls, respectively.

2. Materials and methods {#s0010}
========================

The chemicals and solvents used in this work were purchased from documented international sources and utilized without further purification. The microbiological cultures and anaerobe indicator test were supplied from Sigma-Aldrich. The melting points of the synthesized products were determined on an electrochemical CIA 9300 melting point apparatus using an open capillary method and they were uncorrected. The purity of compounds and the follow up of reactions were checked by ascending TLC on precoated silica gel plates (GF~254~ type 60, Merck); the spots on chromatograms were eluted by CHCl~3~: acetone (4:1) as a mobile phase.

Bruker-Alpha ATR was used to scan IR spectra while the instrument used to identify UV spectra of the synthesized products and to follow up the kinetic study was Varian UV/Visible spectrophotometer. Among other UV absorption bands, the wavelength of maximum absorption (λ~max~) was utilized in this work. Proton-nuclear magnetic resonance (^1^H NMR) and carbon-nuclear magnetic resonance (^13^C NMR) spectra of the synthesized products were scanned on Bruker Avance 300 and 400 MHz. the chemical shifts (δ) of these spectra were expressed in part per million (ppm) downfield to tetramethylsilane as an internal standard. In ^1^H NMR, spin-spin coupling was identified by the following terms: singlet (s), doublet (d), triplet (t) and multiplet (m).

2.1. Synthesis {#s0015}
--------------

### 2.1.1. Synthesis of 4,6-Dimethylcoumarine **(2)** {#s0020}

A solution of *p*-cresol (1.05 ml, 10 mmol) and ethyl acetoacetate (1.4 ml, 11 mmol) was added dropwise over 30 min with a constant stirring to concentrated H~2~SO~4~ (25 ml) placed in an ice bath. The reaction mixture was stirred for 1 h in the ice bath, kept at room temperature overnight, heated to 50 °C and then directly poured into a mixture of crushed ice and H~2~O with vigorous stirring. The precipitate was collected by filtration and washed with H~2~O. The crude product was purified by dissolving it in 50 ml of 10% NaOH solution and the filtrate was then acidified with 1.026 N HCl. The titled product was gathered after 30 min, washed with H~2~O and recrystallized from benzene. This compound was synthesized via a modified method to that reported by ([@b0015]).

*4,6-Dimethylcoumarine* **(2)** off white powder (1.36 g, 78.12% yield), m.p 154--157 °C, λ~max~ (EtOH) 279 nm, R~f~ 0.526, IR (ν, cm^−1^): 3035 (000000000000 000000000000 000000000000 111111111111 000000000000 111111111111 000000000000 000000000000 000000000000C---H str.), 2950 and 2883 (C---H str., alkyl), 1700 (CO str., ester), 1666 (CC str.), 1270 (C---O str., ester); ^1^H NMR (CDCl~3~, 300 MHz) δ ppm: 7.8 (s, 1H, Ar **[H]{.ul}**), 7.5 (d, 1H, Ar **[H]{.ul}**), 7.3 (d, 1H, Ar **[H]{.ul}**), 6.4 (s, 1H, C**[H]{.ul}**), 2.35 (s, 3H, Ar---C**[H]{.ul}**~3~), 1.9 (s, 3H, C---C**[H]{.ul}**~3~); ^13^C NMR (CDCl~3~, 75.47 MHz) δ ppm: 160 (**[C]{.ul}**O), 154 (CH~3~---**[C]{.ul}**C), 143 (Ar **[C]{.ul}**---O), 136 (Ar **[C]{.ul}**---CH~3~), 131, 129.9, 129.7 (Ar **[C]{.ul}**), 124 (Ar **[C]{.ul}**---C---O), 111 (**[C]{.ul}**H), 26 (C---**[C]{.ul}**H~3~), 20 (Ar---**[C]{.ul}**H~3~).

### 2.1.2. Synthesis of 6-Methyl-4-phenylcoumarin (**3**) {#s0025}

Through a solution of *p*-cresol (1.05 ml, 10 mmol) and ethyl benzoylacetate (1.9 ml, 11 mmol) in 30 ml absolute EtOH placed in a two-necked round-bottomed flask wrapped with aluminum foil, dry HCl gas was passed for 3 h under anhydrous conditions. The reaction mixture was kept for 48 h at room temperature and then in refrigerator for 24 h to complete the precipitation. The titled product was filtered, washed with cold EtOH and recrystallized from a mixture of CH~3~OH: ether (1:3). This compound was synthesized via a modified method to that reported by ([@b0105]).

*6-Methyl-4-phenylcoumarin* (**3**) white crystals (1.58 g, 66.79% yield), m.p 132--134 °C, λ~max~ (EtOH) 316 nm, R~f~ 0.704, IR (ν, cm^−1^): 3063 (C---H str.), 2838(C---H str., alkyl), 1700 (CO str., ester), 1641 (CC str.), 1310 (C---O str., ester); ^1^H NMR (CDCl~3~, 300 MHz) δ ppm: 7.7 (s, 1H, Ar **[H]{.ul}**), 7.57 (dd, 2H, Ar **[H]{.ul}**), 7.42 (m, 3H, Arˊ **[H]{.ul}**), 6.6 (s, 1H, C**[H]{.ul}**), 2.1 (s, 3H, Ar---C**[H]{.ul}**~3~); ^13^C NMR (CDCl~3~, 75.47 MHz) δ ppm: 160 (**[C]{.ul}**O), 156 (Arˊ---**[C]{.ul}**), 143 (Ar **[C]{.ul}**---O), 139 (Arˊ **[C]{.ul}**---CCH), 138 (Ar **[C]{.ul}**---CH~3~), 130.8, 130.1, 129.7, 124 (Ar **[C]{.ul}**), 130.2, 129.9, 127 (Arˊ **[C]{.ul}**), 107 (**[C]{.ul}**H), 20 (Ar---**[C]{.ul}**H~3~).

### 2.1.3. General procedure for the reduction of coumarins {#s0030}

A solution of pure LiAlH~4~ (0.76 g, 20 mmol) in 20 ml dry ether was added dropwise to a solution of coumarin derivative (10 mmol) in dry ether placed in an ice bath. After stirring for 15 min at 0 °C, 3 M HCl (8 ml) was gradually added and the pH of the reaction mixture was adjusted to 5 with HCl (1.032 N). The ether layer was dried over anhydrous Na~2~SO~4~, filtered and evaporated. The crude product was dissolved in aqueous EtOH, filtered and evaporated ([@b0070]).

*Z-2-(3-hydroxypropenyl)phenol* **(1a)** white crystals from EtOH (0.60 g, 40.23% yield), m.p 148--151 °C, λ~max~ (EtOH) 286 nm, R~f~ 0.337, IR (ν, cm^−1^): 3301 (phenolic OH, str.), 3276 (alcoholic OH, str.), 3057 (C---H str.), 2894(C---H str., alkyl), 1640 (CC str.); ^1^H NMR (CD~3~OD, 300 MHz) δ ppm: 10 (s, 1H, Ar---O**[H]{.ul}**), 7.05 (d, 1H, Ar **[H]{.ul}**), 6.6--6.7 (dd, 2H, Ar **[H]{.ul}**), 6.4 (d, 1H, Ar **[H]{.ul}**), 6.3 (d, 1H, Ar---C**[H]{.ul}**), 5.75 (m, 1H, C**[H]{.ul}**---CH~2~), 4.25 (d, 2H, C**[H]{.ul}**~2~---OH), 3.5 (s, 1H, CH~2~---O**[H]{.ul}**); ^13^C NMR (CD~3~OD, 100 MHz) δ ppm: 157 (Ar **[C]{.ul}**---OH), 130, 128, 123, 121, 117 (Ar **[C]{.ul}**), 129 (Ar---**[C]{.ul}**H), 127 (**[C]{.ul}**---CH~2~), 62 (**[C]{.ul}**H~2~---OH).

*Z-2-(3-Hydroxy-1-methyl-propenyl)-4-methylphenol* **(2a)** white crystals from EtOH (0.70 g, 39.19% yield), m.p 178--180 °C, λ~max~ (EtOH) 289 nm, R~f~ 0.358, IR (ν, cm^−1^): 3312 (phenolic OH, str.), 3257 (alcoholic OH, str.), 3077 (C---H str.), 2890 (C---H str., alkyl), 1644 (CC str.); ^1^H NMR (CD~3~OD, 300 MHz) δ ppm: 9.9 (s, 1H, Ar---O**[H]{.ul}**), 6.8 (s, 1H, Ar **[H]{.ul}**), 6.5 (d, 1H, Ar **[H]{.ul}**), 6.2 (d, 1H, Ar **[H]{.ul}**), 6.0 (t, 1H, C**[H]{.ul}**), 4.2 (d, 2H, ---C**[H]{.ul}**~2~), 3.5 (s, 1H, CH~2~---O**[H]{.ul}**), 2.5 (s, 3H, Ar---C**[H]{.ul}**~3~), 2 (s, 3H, C---C**[H]{.ul}**~3~); ^13^C NMR (CD~3~OD, 75.47 MHz) δ ppm: 155 (Ar **[C]{.ul}**---OH), 137 (CH~3~---**[C]{.ul}**C), 133 (Ar **[C]{.ul}**---CH~3~), 130, 129, 124, 117 (Ar **[C]{.ul}**), 121 (**[C]{.ul}**H), 62 (**[C]{.ul}**H~2~---OH), 26 (C---**[C]{.ul}**H~3~), 20 (Ar---**[C]{.ul}**H~3~).

*Z-2-(3-Hydroxy-1-phenyl-propenyl)-4-methylphenol* **(3a)** off-white powder from EtOH (0.79 g, 32.89% yield), m.p 140--143 °C, λ~max~ (EtOH) 336 nm, R~f~ 0.567, IR (ν, cm^−1^): 3308 (phenolic OH, str.), 3259 (alcoholic OH, str.), 3063 (C---H str.), 2928, 2883 (C---H str., alkyl), 1642 (CC str.); ^1^H NMR (CD~3~OD, 300 MHz) δ ppm: 9.6 (s, 1H, Ar---O**[H]{.ul}**), 7.3--7.4 (m, 3H, Arˊ **[H]{.ul}**), 6.8 (s, 1H, Ar **[H]{.ul}**), 6.5--6.6 (dd, 2H, Ar **[H]{.ul}**), 6.1 (t, 1H, C**[H]{.ul}**), 4.2 (d, 2H, C**[H]{.ul}**~2~---OH), 4 (s, 1H, CH~2~---O**[H]{.ul}**), 2.1 (s, 3H, Ar---C**[H]{.ul}**~3~); ^13^C NMR (CD~3~OD, 100 MHz) δ ppm: 155 (Ar **[C]{.ul}**---OH), 145 (Arˊ---**[C]{.ul}**), 142 (Arˊ **[C]{.ul}**---CCH), 133 (Ar **[C]{.ul}**---CH~3~), 130, 129.3, 124, 117 (Ar **[C]{.ul}**), 129.7, 128, 127 (Arˊ **[C]{.ul}**), 116 (**[C]{.ul}**H), 62 (**[C]{.ul}**H~2~---OH), 20 (Ar---**[C]{.ul}**H~3~).

### 2.1.4. General procedure for the preparation of disodium salt of diol derivative {#s0035}

A mixture of diol derivative (10 mmol) in 19 ml NaOH (1.029 N) was heated at 60 °C in a water bath with constant stirring for 1 h. The reaction mixture was filtered and the filtrate was evaporated under reduced pressure. The residue was re-dissolved in an adequate amount of DMF, filtered and the filtrate was concentrated to dryness under reduced pressure to afford a disodium salt of diol derivative. This procedure can be considered as a modified one to that reported by ([@b0160]).

### 2.1.5. General procedure for the synthesis of coumacines {#s0040}

To a conical flask enveloped with aluminum foil and lodged in an ice bath, a suspension of disodium salt of diol derivative (10 mmol) in 45 ml dry ethyl acetate was added. As the suspension temperature falls to 0 °C, a solution of methylene iodide (0.4 ml, 5 mmol) in dry ethyl acetate (4.6 ml) was added in portions over 15 min. The reaction mixture was stirred for 6 h at 80 °C and subsequently the solvent was evaporated under reduced pressure. H~2~O (20 ml) was added to the residue and the aqueous layer was extracted with CHCl~3~ (3 × 20 ml). The combined organic layer was dried over CaCl~2~ and evaporated to afford the target product. This procedure can be considered as a modified one to that reported by ([@b0140]).

*4H-Benzo\[d\]\[1,3\]dioxocine* **(coumacine)** white powder from a mixture of ether: CHCl~3~ (1:2), (0.90 g, 55.46% yield), m.p 128--130 °C, λ~max~ (EtOH) 268 nm, R~f~ 0.577, IR (ν, cm^−1^): 3065 (C---H str.), 2900, 2866 (C---H str., alkyl), 1648 (CC str.), 1258 (asymmetrical str. aryl alkyl ether), 1152 (asymmetrical str. aliphatic ether), 1050 (symmetrical str. aryl alkyl ether); ^1^H NMR (CDCl~3~, 300 MHz) δ ppm: 7.0--7.2 (m, 4H, Ar **[H]{.ul}**), 6.8 (d, 1H, Ar---C**[H]{.ul}**), 6.1 (m, 1H, C**[H]{.ul}**---CH~2~), 5.7 (s, 2H, O---C**[H]{.ul}**~2~---O), 3.8 (d, 2H, CH---C**[H]{.ul}**~2~); ^13^C NMR (CDCl~3~, 100 MHz) δ ppm: 158 (Ar **[C]{.ul}**---O---), 128, 127.3, 120.6, 120.4, 111 (Ar **[C]{.ul}**), 127.5 (Ar---**[C]{.ul}**H), 125 (**[C]{.ul}**---CH~2~), 99 (O---**[C]{.ul}**H~2~---O), 63 (CH---**[C]{.ul}**H~2~---O).

*6,8-Dimethyl-4H-benzo\[d\]\[1,3\]dioxocine* **(coumacine I)** white powder from a mixture of ether: CHCl~3~ (1:1.5), (1.18 g, 62.17% yield), m.p 176--178 °C, λ~max~ (EtOH) 279 nm, R~f~ 0.589, IR (ν, cm^−1^): 3078 (C---H str.), 2933, 2888 (C---H str., alkyl), 1650 (CC str.), 1255 (asymmetrical str. aryl alkyl ether), 1157 (asymmetrical str. aliphatic ether), 1067 (symmetrical str. aryl alkyl ether); ^1^H NMR (CDCl~3~, 300 MHz) δ ppm: 7.0 (s, 1H, Ar **H**), 6.7--6.8 (dd, 2H, Ar **H**), 6.1 (t, 1H, C**[H]{.ul}**---CH~2~), 5.8 (s, 2H, O---C**[H]{.ul}**~2~---O), 3.9 (d, 2H, CH---C**[H]{.ul}**~2~), 2.5 (s, 3H, Ar---C**[H]{.ul}**~3~), 2.0 (s, 3H, C---C**[H]{.ul}**~3~); ^13^C NMR (CDCl~3~, 100 MHz) δ ppm: 159 (Ar **[C]{.ul}**---O), 140 (CH~3~---**[C]{.ul}**C), 130 (Ar **[C]{.ul}**---CH~3~), 129.5, 129.0, 122, 114 (Ar **[C]{.ul}**), 119 (**[C]{.ul}**H---CH~2~), 95 (O---**[C]{.ul}**H~2~---O), 66 (CH---**[C]{.ul}**H~2~---O), 25 (C---**[C]{.ul}**H~3~), 20 (Ar---**[C]{.ul}**H~3~).

*8-Methyl-6-phenyl-4H-benzo\[d\]\[1,3\]dioxocine* **(coumacine II)** white powder from a mixture of ether: CHCl~3~ (1:2), (1.99 g, 79.04% yield), m.p 156--159 °C, λ~max~ (EtOH) 288 nm, R~f~ 0.788, IR (ν, cm^−1^): 3066 (C---H str.), 2931, 2837 (C---H str., alkyl), 1652 (CC str.), 1254 (asymmetrical str. aryl alkyl ether), 1144 (asymmetrical str. aliphatic ether), 1045 (symmetrical str. aryl alkyl ether); ^1^H NMR (CDCl~3~, 300 MHz) δ ppm: 7.1--7.3 (m, 3H, Arˊ **[H]{.ul}**), 7 (s, 1H, Ar **[H]{.ul}**), 6.7--6.9 (dd, 2H, Ar **[H]{.ul}**), 6.2 (t, 1H, C**[H]{.ul}**---CH~2~), 5.7 (s, 2H, O---C**[H]{.ul}**~2~---O), 3.9 (d, 2H, CH---C**[H]{.ul}**~2~), 2.2 (s, 3H, Ar---C**[H]{.ul}**~3~); ^13^C NMR (CDCl~3~, 100 MHz) δ ppm: 159 (Ar **[C]{.ul}**---O---), 140 (Arˊ---**[C]{.ul}**CH), 136 (Arˊ **[C]{.ul}**---CCH), 130 (Ar **[C]{.ul}**---CH~3~), 129.5, 127.9, 117, 109 (Ar **[C]{.ul}**), 129.0, 127.3, 127.1 (Arˊ **[C]{.ul}**), 112 (**[C]{.ul}**H---CH~2~), 98 (O---**[C]{.ul}**H~2~---O), 60 (CH---**[C]{.ul}**H~2~---O), 23 (Ar---**[C]{.ul}**H~3~).

2.2. Kinetic study {#s0045}
------------------

The rate of ring closure in the formation of coumacine and its two derivatives was followed up spectrophotometrically and monitored for the increase in the product concentration with time by applying Beer-Lambert law ([@b0010]). At selected time intervals, a drop was taken from a reaction mixture; diluted to 2 ml with EtOH and subsequently estimated at defined λ~max~ to determine the concentration of the formed product.

2.3. Activity against aerobic bacteria {#s0050}
--------------------------------------

The standard aerobic bacterial strains involved in the antibacterial study using ciprofloxacin as a positive control were: *Escherichia coli* ATCC 25922, *Haemophilus influenzae* ATCC 49247, *Klebsiella pneumonia* ATCC 700603 and *Pseudomonas aeruginosa* ATCC 27853. The susceptibility of these bacteria was verified via agar dilution technique using cation-adjusted Mueller-Hinton agar ([@b0055]). Coumacine or one of its derivatives (1 mg) was dissolved in DMSO (1 ml) and then diluted with sterile distilled H~2~O to achieve the following concentrations: 2.5, 5, 10, 25, 50, 100 and 200 µg/ml.

The inoculum of 10^5^ CFU/spot was employed on the agar plates utilizing multiple inoculator (Steers replicator). The inoculated agar plates and that free from the tested compound were incubated at 37 °C for 24 h under aerobic conditions. Afterwards, the minimal inhibitory concentration (MIC) and the percentage of bacterial growth inhibition comparing with negative control of each tested compound were pointed.

2.4. Activity against anaerobic bacteria {#s0055}
----------------------------------------

The investigation of anti-anaerobic activity of coumacine and its two derivatives using metronidazole as a positive control was conducted against the following standard bacterial strains: *Clostridium perfringens* ATCC 13124, *Bacteroides fragilis* ATCC 25285, *Prevotella melaninogenica* ATCC 25845 and *Fusobacterium necrophorum* ATCC 25286. This activity was tested via a plate dilution technique using Brucella agar supported with 5% sheep blood ([@b0060]). Coumacine or one of its derivatives (1 mg) was dissolved in DMSO (1 ml) and then diluted with sterile distilled H~2~O to achieve the following concentrations: 2.5, 5, 10, 25, 50, 100 and 200 µg/ml. The inoculum of 10^5^ CFU/spot was employed on the agar plates utilizing multiple inoculator.

The inoculated agar plates and that free from the tested compound were incubated in an anaerobic jar for 48 h at 37 °C under anaerobic environment which consists of aerophobic atmosphere (10% CO~2~, 10% H~2~ and 80% N~2~), palladium catalyst and anaerobe indicator test. Subsequently, MIC and the percentage of bacterial growth inhibition comparing with negative control of each tested compound were measured.

3. Results and discussion {#s0060}
=========================

Since the gap between antibacterial agents and their efficacy against different pathogenic bacteria has been continuously expanded due to prevalent and haphazard use ([@b0150]), the discovery of new compounds with proven antimicrobial activity becomes an urgent need especially those with unusual heterocyclic structure.

3.1. Synthesis {#s0065}
--------------

The novelty of this work comes from the synthesis of a bicyclic twelve-membered heterocyclic nucleus derived from coumarin by a convenient method as displayed in [Scheme 1](#f0010){ref-type="fig"}; the aforementioned nucleus, herein called coumacine, has not been synthesized before.Scheme 1General synthetic pathway of coumacines.

Coumarins (2) and (3) were prepared via Pechmann condensation though modified methods to those reported by ([@b0015]) and ([@b0105]), respectively. LiAlH~4~, a powerful and non-selective reducing agent, was utilized to reduce coumarins 1, 2 and 3 into corresponding open ring diols 1a, 2a and 3a respectively under restricted reaction conditions of solvent, duration and temperature ([@b0070]).

The resulting diols were transformed to their disodium salts by NaOH to enhance the nucleophilicity of alcoholic and phenolic hydroxyl groups that is required to efficiently attack methylene iodide under anhydrous condition affording coumacine and its two derivatives in acceptable percentage yields.

3.2. Kinetic study {#s0070}
------------------

Based on the parameters obtained from triple trials as shown in [Table 1](#t0005){ref-type="table"}, the rate of ring closure in the formation of synthesized coumacines was found to follow zero order kinetics.Table 1Parameters obtained from the kinetic study.Product nameλ~max~\
(nm, EtOH)ε\
(M^−1^ cm^−1^)k~obs~(M s^−1^)t~1/2~\
(s)Coumacine268416.20.19 × 10^−6^184.21Coumacine I279401.80.28 × 10^−6^175.00Coumacine II288379.60.41 × 10^−6^166.46

The kinetic data used in the application of Beer-Lambert law are listed in [Table 2](#t0010){ref-type="table"} and they indicated that coumacine II was formed in a rate faster than coumacine I, which is formed faster than coumacine. This is possibly due to the bulkiness of electron-donating group substituted on position 4 of the starting materials. It is proposed that as the repulsion between this group and the aromatic constituent of compounds 1b, 2b and 3b increases, the rate of ring closure to form coumacines will increase ([@b0115]).Table 2The kinetic data used in the application of Beer-Lambert law.AbsorbanceProduct nameTime (min.)A (M × 10^6^)0.0025Coumacine306.00670.0030Coumacine I7.46640.0038Coumacine II10.0105  0.0055Coumacine6013.21480.0066Coumacine I16.42610.0088Coumacine II23.1823  0.0077Coumacine9018.50070.0102Coumacine I25.38580.0136Coumacine II35.8272  0.0092Coumacine12022.10480.0130Coumacine I32.35440.0181Coumacine II47.6818  0.0122Coumacine15029.31280.0165Coumacine I41.06520.0213Coumacine II56.1117  0.0146Coumacine18035.07930.0197Coumacine I49.02940.0260Coumacine II68.4932  0.0167Coumacine21040.12490.0236Coumacine I58.73570.0315Coumacine II82.9821  0.0197Coumacine24047.33300.0253Coumacine I62.96670.0349Coumacine II91.9389  0.0216Coumacine27051.89810.0299Coumacine I74.41510.0400Coumacine II105.3741  0.0242Coumacine30058.14510.0328Coumacine I81.63270.0430Coumacine II113.2771  0.0267Coumacine33064.15190.0363Coumacine I90.34350.0481Coumacine II126.7123  0.0291Coumacine36069.91830.0394Coumacine I98.05870.0522Coumacine II137.5132

3.3. Antibacterial activity {#s0075}
---------------------------

Novel coumacines were screened for their antibacterial activity against four standard aerobic bacterial strains (*Escherichia coli* ATCC 25922, *Haemophilus influenzae* ATCC 49247, *Klebsiella pneumonia* ATCC 700603 and *Pseudomonas aeruginosa* ATCC 27853) and against four standard anaerobic bacterial strains (*Clostridium perfringens* ATCC 13124, *Bacteroides fragilis* ATCC 25285, *Prevotella melaninogenica* ATCC 25845 and *Fusobacterium necrophorum* ATCC 25286) via agar dilution method using a solution of ciprofloxacin or of metronidazole as a positive control, respectively.

The results of this preliminary screening study as shown in [Table 3](#t0015){ref-type="table"} indicated that coumacine I has an excellent antibacterial activity against the tested aerobic and anaerobic bacteria with percentages of growth inhibition approximating to those of ciprofloxacin and metronidazole; so, this novel compound can be considered as an encouraging broad spectrum antibacterial agent. Although coumacine and coumacine II have a narrow spectrum and less potent antibacterial activity compared with coumacine I, they can be also regarded as heartening candidates for further microbiological screening tests.Table 3The MIC (μg/ml) and percentage of bacterial growth inhibition for the synthesized products and positive controls.Aerobic bacteriaCiprofloxacinCoumacineCoumacine ICoumacine IIMIC%MIC%MIC%MIC%*Escherichia coli*0.808710054.3580.55052.2*Haemophilus influenzae*0.6582N--2556.9N--*Klebsiella pneumonia*0.5885048.5579.320049.4*Pseudomonas aeruginosa*0.769220035.9577.9N--  Anaerobic bacteriaMetronidazoleCoumacineCoumacine ICoumacine IIMIC%MIC%MIC%MIC%*Clostridium perfringens*0.7885N--1065.3N--*Bacteroides fragilis*3.5942539.9582.710037.8*Prevotella melaninogenica*0.6592N--582.3533.1*Fusobacterium necrophorum*1.6905033.8578.85036.7[^1]

4. Conclusion {#s0080}
=============

Novel oxygenated heterocyclic nucleus termed coumacine in addition to two of its derivatives were prepared with good yields via a facile synthetic pathway, and their chemical structures were characterized by detecting their physicochemical properties and analyzing their IR, ^1^H NMR and ^13^C NMR spectra. The rate of their ring closure was studied via UV/Vis spectroscopy and followed zero order kinetics. The synthesized products were screened for their antibacterial activity against different aerobic and anaerobic standard bacterial strains. Although the three final products showed encouraging antibacterial activity, coumacine I has a broader and more potent activity compared with the other two using agar dilution method.

Peer review under responsibility of King Saud University.

[^1]: N = no antibacterial activity at 200 µg/ml.
